Mouse anti-Human HLA-DR Monoclonal Antibody | anti-HLA-DR antibody

Anti-Human HLA-DR Monoclonal Antibody (APC Conjugated)

Cat. Num. AAA2553969

• Gene Names: HLA-DRA; HLA-DRA1
• Reactivity: Human
• Applications: Flow Cytometry, Functional Assay, Western Blot, Immunohistochemistry, Immunoprecipitation
• Synonyms: HLA-DR; Monoclonal Antibody; Anti-Human HLA-DR Monoclonal Antibody (APC Conjugated); Human HLA-DR; HLA class II histocompatibility antigen DR alpha/ DRB1-15 beta chain; MHC class II antigen DRA; HLA-DRA1/DRB1; DRA/DRB1; anti-HLA-DR antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG2a
• Clone Number: L243
• Form/Format: Liquid; PBS with 0.05% Proclin300, 1% BSA
• Sequence Length: 254

• Applicable Applications for anti-HLA-DR antibody: Flow Cytometry (FC/FACS), Western Blot (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP)
• Application Notes: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The amount of the reagent is suggested to be used 5 muL of antibody per test (million cells in 100 ul staining volume or per 100 ul of whole blood). Please check your vial before the experiment.
• Conjugation: APC
• Cellular Localization: Membrane
• Preparation and Storage: Store at 2-8 degree C. Protected from prolonged exposure to light.

Related Product Information for anti-HLA-DR antibody

The LN3 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD alpha (heavy) chain and a 27 kD beta (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells.

References

1. Levacher M, et al. 1990. Clin. Exp. Immunol. 81:177. 2. Terstappen L, et al. 1990. J. Leuk. Biol. 48:138. 3. Edwards J, et al. 1985. J. Immunol. 137:490. 4. van Es A, et al. 1984. Transplantation 37:65. 5. O'Doherty U, et al. 1994. Immunology 82:487. 6. Thomas R, et al. 1994. J. Immunol. 153:4016. 7. Grouard G, et al. 1996. Nature 384:364.

NCBI and Uniprot Product Information

• NCBI GI #: 52426774
• NCBI GeneID: 3122
• NCBI Accession #: NP_061984.2
• NCBI GenBank Nucleotide #: NM_019111.5
• UniProt Accession #: P01903; Q30160; Q6IAZ1; Q861I2; Q9TP70; A2BET4
• Molecular Weight: 28,607 Da
• NCBI Official Full Name: HLA class II histocompatibility antigen, DR alpha chain
• NCBI Official Synonym Full Names: major histocompatibility complex, class II, DR alpha
• NCBI Official Symbol: HLA-DRA
• NCBI Official Synonym Symbols: HLA-DRA1
• NCBI Protein Information: HLA class II histocompatibility antigen, DR alpha chain
• UniProt Protein Name: HLA class II histocompatibility antigen, DR alpha chain
• UniProt Gene Name: HLA-DRA
• UniProt Synonym Gene Names: HLA-DRA1

NCBI Description

HLA-DRA is one of the HLA class II alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The alpha chain is approximately 33-35 kDa and its gene contains 5 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5. [provided by RefSeq, Jul 2008]

Uniprot Description

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.